Abstract:<p>Lysine-specific demethylase 1 (LSD1/KDM1A) has emerged as a promising target for the discovery of specific inhibitors as antitumor drugs. Based on the source of compounds, all LSD1 inhibitors in this review were divided into two categories: natural LSD1 inhibitors and synthetic LSD1 inhibitors. This review highlights the research progress of LSD1 inhibitors with the potential to treat cancer covering articles published in 2020. Design strategies, structure-activity relationships, co-crystal structure analysis and action mechanisms were also highlighted.</p>

What problem does this paper attempt to address?

This paper aims to review the progress in the research field of LSD1/KDM1A inhibitors in 2020, with special attention to the potential applications of these inhibitors in cancer treatment. LSD1 (also known as KDM1A) is a specific lysine demethylase, which is abnormally over - expressed in acute myeloid leukemia and solid tumors, promoting cell proliferation, inhibiting differentiation and enhancing cell motility. Therefore, LSD1 has become an attractive target for the design of anti - tumor drugs. In the paper, the authors divide all LSD1 inhibitors into two major categories according to the origin of the compounds: natural LSD1 inhibitors and synthetic LSD1 inhibitors. The design strategies, structure - activity relationships, co - crystal structure analysis and their mechanisms of action of these inhibitors are discussed in detail. Through these studies, the authors hope to provide opportunities for further research and optimization of new LSD1 inhibitors for cancer treatment. Specifically, the paper covers the following parts: 1. **Introduction**: Introduces the epigenetic regulatory role of histone lysine methylation in gene expression and chromatin structure, and the role of LSD1 in this process. 2. **Natural LSD1 inhibitors**: Summarizes the research progress of natural LSD1 inhibitors published in 2020, including capsaicin, alkaloid A, natural LSD1 inhibitors in Salvia miltiorrhiza roots and natural isoquinoline alkaloids. 3. **Synthetic LSD1 inhibitors**: Discusses the research progress of synthetic LSD1 inhibitors in 2020, including tetrahydroquinoline, clinical candidate CC - 90011, thiophene[3,2 - b]pyrrole, trans - 2 - phenylcyclopropylamine derivatives, [1 - 3]triazole[4,5 - d]pyrimidine, 5 - cyano - 6 - phenylpyrimidine, 7 - oxabicyclo[2.2.1]hept - 5 - en - 2 - sulfonate, 4 - hydroxy - 3 - methylbenzofuran - 2 - acylhydrazone and macrocyclic peptides, etc. 4. **Conclusion and Outlook**: Summarizes the current research achievements of LSD1 inhibitors and looks forward to future research directions. Through these contents, the paper not only provides the latest research trends of LSD1 inhibitors, but also provides valuable information and references for future researchers.

Annual review of LSD1/KDM1A inhibitors in 2020

LSD1 inhibitors for anticancer therapy: a patent review (2017-present)

Lysine-Specific Demethylase 1 Inhibitors: A Comprehensive Review Utilizing Computer-Aided Drug Design Technologies

Therapeutic potential of targeting LSD1/ KDM1A in cancers

LSD1/KDM1A Inhibitors in Clinical Trials: Advances and Prospects

Promising natural lysine specific demethylase 1 inhibitors for cancer treatment: advances and outlooks

LSD1 inhibitors for cancer treatment: Focus on multi-target agents and compounds in clinical trials

Pharmacological Inhibition of LSD1 for Cancer Treatment

Recent advances in inhibitors of lysine specific demethylase 1 in tumor therapies

Medicinal Chemistry Insights in the Discovery of Novel LSD1 Inhibitors

Design, Synthesis, and Structure-Activity Relationship of Novel LSD1 Inhibitors Based on Pyrimidine-Thiourea Hybrids As Potent, Orally Active Antitumor Agents.

Targeting LSD1 in cancer: Molecular elucidation and recent advances

Development of the Triazole-Fused Pyrimidine Derivatives As Highly Potent and Reversible Inhibitors of Histone Lysine Specific Demethylase 1 (LSD1/KDM1A)

Utilizing a structure-based virtual screening approach to discover potential LSD1 inhibitors

Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer

Structure–Activity Relationship Study of Indolin-5-yl-cyclopropanamine Derivatives as Selective Lysine Specific Demethylase 1 (LSD1) Inhibitors

Targeting LSD1 for acute myeloid leukemia (AML) treatment

Drug discovery of histone lysine demethylases (KDMs) inhibitors (progress from 2018 to present)

Optimization and Biological Evaluation of Novel 1H-Pyrrolo[2,3-c]pyridin Derivatives As Potent and Reversible Lysine Specific Demethylase 1 Inhibitors for the Treatment of Acute Myelogenous Leukemia

Design, Synthesis and Biological Activity of 4-(4-benzyloxy)phenoxypiperidines As Selective and Reversible LSD1 Inhibitors.

Combination Therapy and Dual-Target Inhibitors Based on LSD1: New Emerging Tools in Cancer Therapy